Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) EBT Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBT Margin for 7 consecutive years, with 5.96% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 29455.0% to 5.96% in Q4 2025 year-over-year; TTM through Dec 2025 was 237.04%, a 34597.0% increase, with the full-year FY2025 number at 57.24%, up 53582.0% from a year prior.
  • EBT Margin was 5.96% for Q4 2025 at Beam Therapeutics, up from 1162.38% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 45.83% in Q4 2023 to a low of 3339900.0% in Q1 2021.
  • A 5-year average of 216895.26% and a median of 618.17% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -287726667bps in 2021, then surged 333900364bps in 2022.
  • Beam Therapeutics' EBT Margin stood at 124.2% in 2021, then tumbled by -227bps to 406.12% in 2022, then skyrocketed by 111bps to 45.83% in 2023, then crashed by -756bps to 300.51% in 2024, then skyrocketed by 98bps to 5.96% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's EBT Margin are 5.96% (Q4 2025), 1162.38% (Q3 2025), and 1208.26% (Q2 2025).